ArticleBMC cardiovascular disorders2026
Impact of residual cholesterol and inflammation risk on non-culprit plaque progression in patients with acute coronary syndrome: a serial optical coherence tomography study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundAcute Coronary Syndrome (ACS) patients face recurrent cardiovascular events due to non-culprit plaque progression despite optimal secondary prevention, but the differential impacts of residual cholesterol risk (RCR, on-treatment LDL-C ≥ 1.8mmol/L) and residual inflammation risk (RIR, on-treatment hs-CRP ≥2 mg/L) on plaque microstructure dynamics remain undefined. This study aimed to clarify how residual cholesterol and inflammatory risk factors differentially modulate the progression of non-culprit plaques in patients with ACS using serial optical coherence tomography (OCT).
methodsA retrospective cohort of 243 ACS patients underwent baseline and 1-year (9-15 months) follow-up OCT. Patients were stratified into four groups (RCR, RIR, combined residual cholesterol-inflammation risk [RCIR], no residual risk). OCT assessed plaque morphology (e.g., thin-cap fibroatheroma [TCFA]) and quantitative parameters (lumen area, fibrous cap thickness [FCT], lipid arc). Multivariate logistic regression identified factors associated with plaque progression (defined as a decrease in minimal lumen area > 0.5 mm² from baseline to follow-up) and TCFA persistent.
resultsOf 583 evaluable non-culprit lesions, RIR was independently associated with patient-level plaque progression (odds ratio [OR]: 2.915, 95% confidence interval [CI]: 1.005-9.212, P = 0.046) and was linked to significant reductions in reference, mean, and minimal lumen area (all P < 0.05) vs. the no-risk group. RCR was associated with attenuated lipid plaque regression compared with the no residual risk group, as evidenced by smaller min-FCT increases (20.0 [-13.3, 73.3] µm vs. 50.0 [18.3, 86.7] µm, P = 0.014) and attenuated mean lipid arc reductions (-8.8 ± 27.1° vs. -17.7 ± 23.6°, P = 0.027). RCR (OR: 4.462, 95%CI: 1.723-12.521, P = 0.003) and RCIR (OR: 4.892, 95%CI: 1.623-15.467, P = 0.005) were independently associated with follow-up TCFA persistent.
conclusionsThis study demonstrated distinct associations of RIR and RCR with non-culprit plaque progression: RIR was linked to luminal narrowing, while RCR attenuated lipid plaque stabilization. These findings provide imaging-based insights into plaque dynamics and may inform future risk stratification and residual risk management strategies in ACS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.